PT1207860E - Formulação de peletes de libertação controlada - Google Patents
Formulação de peletes de libertação controlada Download PDFInfo
- Publication number
- PT1207860E PT1207860E PT00974064T PT00974064T PT1207860E PT 1207860 E PT1207860 E PT 1207860E PT 00974064 T PT00974064 T PT 00974064T PT 00974064 T PT00974064 T PT 00974064T PT 1207860 E PT1207860 E PT 1207860E
- Authority
- PT
- Portugal
- Prior art keywords
- release
- water
- present
- insoluble
- coating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15211599P | 1999-09-02 | 1999-09-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1207860E true PT1207860E (pt) | 2008-01-24 |
Family
ID=22541572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT00974064T PT1207860E (pt) | 1999-09-02 | 2000-08-30 | Formulação de peletes de libertação controlada |
Country Status (12)
Country | Link |
---|---|
US (2) | US6475493B1 (pt) |
EP (1) | EP1207860B1 (pt) |
JP (1) | JP2003508422A (pt) |
AT (1) | ATE376414T1 (pt) |
AU (1) | AU781048B2 (pt) |
BR (1) | BR0013720A (pt) |
CA (1) | CA2383220C (pt) |
DE (1) | DE60036874T2 (pt) |
ES (1) | ES2295062T3 (pt) |
NZ (1) | NZ517465A (pt) |
PT (1) | PT1207860E (pt) |
WO (1) | WO2001015668A1 (pt) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010055613A1 (en) * | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
US8257744B2 (en) * | 2000-07-07 | 2012-09-04 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
EP2060253A1 (en) | 2007-11-14 | 2009-05-20 | Laboratorios Farmaceuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
DE10211289A1 (de) | 2002-03-14 | 2003-09-25 | Basf Ag | Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität |
WO2003096874A2 (en) * | 2002-05-15 | 2003-11-27 | Sun Pharmaceutical Industries Limited | Coated sustained release tablets of a hygroscopic compound for once-a-day therapy |
US7649023B2 (en) | 2002-06-11 | 2010-01-19 | Novartis Ag | Biodegradable block copolymeric compositions for drug delivery |
US7018658B2 (en) * | 2002-11-14 | 2006-03-28 | Synthon Bv | Pharmaceutical pellets comprising tamsulosin |
US7988993B2 (en) * | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
DE10260921A1 (de) * | 2002-12-20 | 2004-07-01 | Röhm GmbH & Co. KG | Verfahren zum Überziehen von Substraten für pharmazeutische Anwendungen mit einem Gemisch aus zwei filmbildenden Überzugsmitteln |
DE10260919A1 (de) * | 2002-12-20 | 2004-07-01 | Röhm GmbH & Co. KG | Verfahren zur Herstellung von überzogenen Arzneiformen und Nahrungsergänzungsmitteln mit Konzentrationsgradienten im Überzug |
TW200503670A (en) * | 2003-03-28 | 2005-02-01 | Sandoz Ag | Venlafaxine compositions |
JP4808612B2 (ja) * | 2003-04-25 | 2011-11-02 | 田辺三菱製薬株式会社 | アルキレンジオキシベンゼン誘導体を含む経口投与用組成物 |
WO2005046663A1 (en) | 2003-11-04 | 2005-05-26 | Shire Laboratories, Inc. | Compositions of quaternary ammonium containing bioavailability enhancers |
MXPA06003769A (es) * | 2003-11-04 | 2006-07-03 | Shire Lab Inc | Liberacion sostenida de moleculas farmacologicamente activas cargadas positivamente a partir de una matriz que contiene polimeros con atomos de oxigeno polarizados. |
JP5610663B2 (ja) | 2003-11-04 | 2014-10-22 | スパーナス ファーマシューティカルズ インコーポレイテッド | トロスピウムの1日1回剤形 |
US20050106253A1 (en) * | 2003-11-13 | 2005-05-19 | Platteeuw Johannes J. | Pharmaceutical pellets comprising tamsulosin |
US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
US7989452B2 (en) * | 2003-12-23 | 2011-08-02 | Bioniche Teoranta | Stable hydrazalazine pharmaceutical compositions |
CA2547843A1 (en) * | 2004-02-09 | 2005-08-18 | Transfert Plus Societe En Commandite | Composition comprising polymeric material and uses thereof |
KR100615952B1 (ko) * | 2004-05-27 | 2006-08-28 | 한국화학연구원 | 서방형 약물 전달 시스템 |
US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
NZ555693A (en) | 2004-12-27 | 2010-10-29 | Eisai R&D Man Co Ltd | Matrix type sustained-release preparation containing donepezil |
US20070071819A1 (en) * | 2005-05-30 | 2007-03-29 | Kesarwani Amit K | Multiple unit modified release compositions of carbamazepine and process for their preparation |
DK1915137T3 (da) | 2005-08-10 | 2013-11-04 | Add Advanced Drug Delivery Technologies Ltd | Oralt præparat med kontrolleret frisætning |
WO2007025005A2 (en) | 2005-08-24 | 2007-03-01 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
US8394812B2 (en) | 2005-08-24 | 2013-03-12 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
US20070048373A1 (en) | 2005-08-30 | 2007-03-01 | Cima Labs Inc. | Dried milled granulate and methods |
AU2007208214B2 (en) * | 2006-01-24 | 2013-02-14 | Paratek Pharmaceuticals, Inc. | Methods of increasing oral bioavailability of tetracyclines |
EP1976492B8 (en) * | 2006-01-27 | 2018-07-04 | Adare Pharmaceuticals, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
EP1981487B1 (en) * | 2006-02-07 | 2014-06-25 | Fmc Corporation | Latex or pseudolatex compositions coatings and coating processes |
US8846100B2 (en) | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
JP5230613B2 (ja) | 2006-05-23 | 2013-07-10 | テラコス・インコーポレイテッド | グルコース輸送体阻害剤およびその使用方法 |
US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
EP1872779A1 (de) * | 2006-06-28 | 2008-01-02 | Oramon Arzneimittel GmbH | Stabile multipartikuläre pharmazeutische Zusammensetzung von tri- und tetracyclischen Antidepressiva |
EA018036B1 (ru) | 2006-11-27 | 2013-05-30 | Х. Лундбекк А/С | Гетероариламидные производные |
AU2008232419B2 (en) | 2007-04-02 | 2013-06-20 | Theracos, Inc. | Benzylic glycoside derivatives and methods of use |
US20080268047A1 (en) * | 2007-04-24 | 2008-10-30 | Xavier University Of Louisiana | Controlled Release Multiple Layer Coatings |
PL2187742T3 (pl) | 2007-08-23 | 2018-06-29 | Theracos Sub, Llc | Pochodne (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylofenylo)-6-(hydroksymetylo) tetrahydro-2h-pirano-3,4,5-triolu do stosowania w leczeniu cukrzycy |
US20090136650A1 (en) * | 2007-09-18 | 2009-05-28 | Viva Pharmaceuticals Inc. | Enteric coatings for orally ingestible compositions |
US20090074944A1 (en) * | 2007-09-18 | 2009-03-19 | Viva Pharmaceuticals Inc. | Enteric coatings for orally ingestible compositions |
US20110091566A1 (en) * | 2007-09-25 | 2011-04-21 | Nirmal Mulye | Controlled release pharmaceutical compositions |
US8802156B2 (en) | 2007-11-14 | 2014-08-12 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
PL2268160T3 (pl) * | 2008-03-20 | 2013-05-31 | Virun Inc | Emulsje zawierające pochodną PEG tokoferolu |
MX2010010214A (es) | 2008-03-20 | 2010-12-21 | Virun Inc | Derivados de vitamina e y sus usos. |
TWI523652B (zh) | 2008-07-15 | 2016-03-01 | 泰瑞克公司 | 氘化苄基苯衍生物及使用方法 |
AR073118A1 (es) | 2008-08-22 | 2010-10-13 | Theracos Inc | Procesos para la preparacion de inhibidores de sglt2 y formas cristalinas del mismo. |
AU2009311877C1 (en) * | 2008-11-07 | 2013-08-15 | Samyang Holdings Corporation | Pharmaceutical composition for release control of methylphenidate |
AU2009324894B2 (en) | 2008-11-25 | 2015-04-09 | University Of Rochester | MLK inhibitors and methods of use |
KR101152977B1 (ko) * | 2009-12-14 | 2012-06-11 | 근화제약주식회사 | 약제학적 제제 |
CN103037708B (zh) | 2010-03-23 | 2015-05-20 | 维尔恩公司 | 含有蔗糖脂肪酸酯的纳米乳液 |
CA2800176C (en) | 2010-05-24 | 2018-08-28 | University Of Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
IT1401146B1 (it) * | 2010-07-27 | 2013-07-12 | Gnosis Spa | Composizione comprendente shellac e/o un suo sale e sodio amido glicolato |
US20120039999A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
US8808736B2 (en) | 2011-02-11 | 2014-08-19 | Zx Pharma, Llc | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
PL2672981T3 (pl) | 2011-02-11 | 2018-09-28 | Zx Pharma, Llc | Wielocząstkowe preparaty l-mentolu i powiązane sposoby |
US8911780B2 (en) | 2011-02-11 | 2014-12-16 | Zx Pharma, Llc | Multiparticulate L-menthol formulations and related methods |
US9592288B2 (en) | 2011-02-18 | 2017-03-14 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
US8524664B2 (en) | 2011-06-02 | 2013-09-03 | Colorado Seminary, Which owns and Operates The Univeristy of Denver | Methods of treating overproduction of cortisol using ACTH antagonist peptides |
US8828426B2 (en) * | 2011-06-07 | 2014-09-09 | Zx Pharma, Llc | Multiparticulate L-carnitine compositions and related methods |
WO2014085795A1 (en) | 2012-11-30 | 2014-06-05 | University Of Rochester | Mixed lineage kinase inhibitors for hiv/aids therapies |
US9351517B2 (en) | 2013-03-15 | 2016-05-31 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and compositions containing same |
WO2014175852A1 (en) | 2013-04-23 | 2014-10-30 | Zx Pharma, Llc | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
WO2015170195A1 (en) * | 2014-05-03 | 2015-11-12 | GORREPATI, Navaneeta Krishna | Hydrazaline hydrochloride pellets and its preparation method |
US9861611B2 (en) | 2014-09-18 | 2018-01-09 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5518694B2 (pt) * | 1973-04-02 | 1980-05-21 | ||
DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
JPS587607B2 (ja) * | 1978-12-18 | 1983-02-10 | 信越化学工業株式会社 | 腸溶性被覆製剤の製造方法 |
FR2471186A1 (fr) | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
DE3000979A1 (de) | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
US4282233B1 (en) | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
DE3126703A1 (de) | 1981-07-07 | 1983-01-27 | Dr. Karl Thomae Gmbh, 7950 Biberach | Bromhexin-retardform und verfahren zu ihrer herstellung |
US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
JPS59193831A (ja) | 1983-04-18 | 1984-11-02 | Sankyo Co Ltd | 腸溶性製剤の製造法 |
DE3403329A1 (de) | 1984-02-01 | 1985-08-01 | Horst Dr. 4019 Monheim Zerbe | Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe |
US4568559A (en) | 1984-02-06 | 1986-02-04 | Biotek, Inc. | Composite core coated microparticles and process of preparing same |
US4623588A (en) | 1984-02-06 | 1986-11-18 | Biotek, Inc. | Controlled release composite core coated microparticles |
JPS61501205A (ja) | 1984-02-15 | 1986-06-19 | シェリング・コ−ポレ−ション | 8↓−クロル↓−6,11↓−ジヒドロ↓−11↓−(4↓−ピペリジリデン)↓−5H↓−ベンゾ〔5,6〕シクロヘプタ〔1,2−b〕ピリジンおよびその塩、これらの化合物の製造方法、ならびにこれらの化合物を含有する医薬組成物 |
US4568560A (en) * | 1984-03-16 | 1986-02-04 | Warner-Lambert Company | Encapsulated fragrances and flavors and process therefor |
GB8414220D0 (en) | 1984-06-04 | 1984-07-11 | Sterwin Ag | Medicaments in unit dose form |
GB8427218D0 (en) | 1984-10-27 | 1984-12-05 | Scras | Pyridine derivatives |
US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
DE3524337A1 (de) * | 1985-07-08 | 1987-01-08 | Roehm Gmbh | Arzneimittelumhuellung |
GB8519310D0 (en) | 1985-07-31 | 1985-09-04 | Zyma Sa | Granular active substances |
LU86077A1 (fr) | 1985-09-18 | 1987-04-02 | Pharlyse Sa | Nouvelles formes galeniques du verapamil,leur fabrication et medicaments contenant ces nouvelles formes galeniques |
LU86099A1 (fr) | 1985-09-30 | 1987-04-02 | Pharlyse | Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant |
US5238686A (en) | 1986-03-27 | 1993-08-24 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
US4756911A (en) * | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4808413A (en) | 1987-04-28 | 1989-02-28 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions in the form of beadlets and method |
US4904474A (en) * | 1988-01-25 | 1990-02-27 | Alza Corporation | Delivery of drug to colon by oral disage form |
US5277916A (en) | 1988-02-01 | 1994-01-11 | F. H. Faulding & Co., Ltd. | Tetracycline dosage form |
US5472710A (en) | 1988-04-16 | 1995-12-05 | Schwarz Pharma Ag | Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture |
CA2007181C (en) * | 1989-01-06 | 1998-11-24 | Angelo Mario Morella | Sustained release pharmaceutical composition |
US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5330766A (en) | 1989-01-06 | 1994-07-19 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
CA2007055A1 (en) * | 1989-01-06 | 1990-07-06 | Garth Boehm | Theophylline dosage form |
ES2077023T3 (es) * | 1989-03-10 | 1995-11-16 | Yamanouchi Pharma Co Ltd | Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada. |
US5026559A (en) | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
US5540945A (en) | 1989-05-11 | 1996-07-30 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines |
US5084287A (en) | 1990-03-15 | 1992-01-28 | Warner-Lambert Company | Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat |
JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
US5288505A (en) | 1991-06-26 | 1994-02-22 | Galephar P.R., Inc., Ltd. | Extended release form of diltiazem |
US5213811A (en) * | 1991-09-13 | 1993-05-25 | Sterling Drug Inc. | Oral sustained-release drug compositions |
US5169638A (en) | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
NZ253999A (en) | 1992-08-05 | 1996-07-26 | Faulding F H & Co Ltd | Pelletised substained release medicament |
JP2916978B2 (ja) | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | 放出開始制御型製剤 |
JPH08143476A (ja) * | 1994-11-18 | 1996-06-04 | Japan Tobacco Inc | 薬物放出制御膜及び固形製剤 |
US5834024A (en) | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
US5837379A (en) * | 1997-01-31 | 1998-11-17 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
JP3611456B2 (ja) * | 1997-09-30 | 2005-01-19 | 日研化学株式会社 | テオフィリン徐放性錠剤 |
-
2000
- 2000-08-30 NZ NZ517465A patent/NZ517465A/en unknown
- 2000-08-30 ES ES00974064T patent/ES2295062T3/es not_active Expired - Lifetime
- 2000-08-30 CA CA002383220A patent/CA2383220C/en not_active Expired - Fee Related
- 2000-08-30 AT AT00974064T patent/ATE376414T1/de not_active IP Right Cessation
- 2000-08-30 DE DE60036874T patent/DE60036874T2/de not_active Expired - Lifetime
- 2000-08-30 JP JP2001519882A patent/JP2003508422A/ja active Pending
- 2000-08-30 PT PT00974064T patent/PT1207860E/pt unknown
- 2000-08-30 WO PCT/US2000/040783 patent/WO2001015668A1/en active IP Right Grant
- 2000-08-30 BR BR0013720-0A patent/BR0013720A/pt not_active Application Discontinuation
- 2000-08-30 AU AU12492/01A patent/AU781048B2/en not_active Ceased
- 2000-08-30 EP EP00974064A patent/EP1207860B1/en not_active Expired - Lifetime
- 2000-08-30 US US09/650,838 patent/US6475493B1/en not_active Expired - Fee Related
-
2002
- 2002-06-10 US US10/165,907 patent/US6635680B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20020192285A1 (en) | 2002-12-19 |
WO2001015668A1 (en) | 2001-03-08 |
CA2383220A1 (en) | 2001-03-08 |
AU1249201A (en) | 2001-03-26 |
JP2003508422A (ja) | 2003-03-04 |
EP1207860A4 (en) | 2005-07-13 |
DE60036874T2 (de) | 2008-06-26 |
EP1207860B1 (en) | 2007-10-24 |
US6475493B1 (en) | 2002-11-05 |
EP1207860A1 (en) | 2002-05-29 |
ATE376414T1 (de) | 2007-11-15 |
CA2383220C (en) | 2009-11-03 |
NZ517465A (en) | 2003-10-31 |
ES2295062T3 (es) | 2008-04-16 |
DE60036874D1 (de) | 2007-12-06 |
US6635680B2 (en) | 2003-10-21 |
AU781048B2 (en) | 2005-05-05 |
BR0013720A (pt) | 2002-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1207860E (pt) | Formulação de peletes de libertação controlada | |
NZ510384A (en) | Sustained release ranolazine formulations | |
IL150696A0 (en) | Pharmaceutical compositions containing benzimidazole derivatives and processes for the manufacture thereof | |
SG80553A1 (en) | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract | |
PL356962A1 (en) | Multi-particulate form of medicament, comprising at least two differently coated forms of pellet | |
BG105061A (en) | Enteric coated pharmaceutical composition and method of manufacturing | |
ZA9711536B (en) | Antitussive drugs delivered by ion exchange resins. | |
IL111647A0 (en) | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles, their preparation and pharmaceutical compositions containing them | |
AU6770490A (en) | Solid pharmaceutical compositions containing cimetidine | |
CA2136871A1 (en) | Composition and method for inducing satiety | |
IE61503B1 (en) | Controlled release formulation | |
CA2141582A1 (en) | Pelletised pharmaceutical composition | |
CA2149362A1 (en) | Pharmaceutical composition based on guar gum coated with simethicone, inassociation with a neutralizing antacid | |
EP0377517A3 (en) | Theophylline dosage form | |
BR0012326A (pt) | Formulações lìquidas farmacêuticas de gosto mascarado | |
IL161628A0 (en) | Pharmaceutical dosage form with multiple coatings | |
CA2299423A1 (en) | Taste-masked pharmaceutical composition | |
Schurig et al. | Antiemetic activity of butorphanol against cisplatin-induced emesis in ferrets and dogs | |
WO1999042087A3 (en) | Controlled release potassium chloride pellet based pharmaceutical compositions having a high active ingredient content | |
WO1997010810A3 (en) | Pharmaceutical granules | |
JPS54126722A (en) | Slow release antibiotic tablet | |
JPS5545601A (en) | Long-acting cephalexin and its preparation | |
SE8902699D0 (sv) | Diltiazem containing pharmaceutical compositios | |
JPS5659707A (en) | Lasting antibiotic pharmaceutical and its preparation | |
WO2005120467A3 (de) | Arzneiform, enthaltend den wirkstoff cholylsarcosin |